Correlation Between Opus Genetics, and Telix Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Opus Genetics, and Telix Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Opus Genetics, and Telix Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Opus Genetics, and Telix Pharmaceuticals Limited, you can compare the effects of market volatilities on Opus Genetics, and Telix Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Opus Genetics, with a short position of Telix Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Opus Genetics, and Telix Pharmaceuticals.

Diversification Opportunities for Opus Genetics, and Telix Pharmaceuticals

0.14

Correlation Coefficient

Opus Genetics,  Telix Pharmaceuticals

Average diversification

The 3 months correlation between Opus and Telix is 0.14. Overlapping area represents the amount of risk that can be diversified away by holding Opus Genetics, and Telix Pharmaceuticals Limited in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Telix Pharmaceuticals and Opus Genetics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Opus Genetics, are associated (or correlated) with Telix Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Telix Pharmaceuticals has no effect on the direction of Opus Genetics, i.e., Opus Genetics, and Telix Pharmaceuticals go up and down completely randomly.

Pair Corralation between Opus Genetics, and Telix Pharmaceuticals

Considering the 90-day investment horizon Opus Genetics, is expected to under-perform the Telix Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Opus Genetics, is 39.89 times less risky than Telix Pharmaceuticals. The stock trades about -0.03 of its potential returns per unit of risk. The Telix Pharmaceuticals Limited is currently generating about 0.19 of returns per unit of risk over similar time horizon. If you would invest  0.00  in Telix Pharmaceuticals Limited on September 24, 2024 and sell it today you would earn a total of  1,582  from holding Telix Pharmaceuticals Limited or generate 9.223372036854776E16% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	5.62%
Values	Daily Returns

Opus Genetics,  vs.  Telix Pharmaceuticals Limited

Opus Genetics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Opus Genetics, has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Telix Pharmaceuticals

Risk-Adjusted Performance

6 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Telix Pharmaceuticals Limited are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak essential indicators, Telix Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Pair Trading with Opus Genetics, and Telix Pharmaceuticals

The main advantage of trading using opposite Opus Genetics, and Telix Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Opus Genetics, position performs unexpectedly, Telix Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Telix Pharmaceuticals will offset losses from the drop in Telix Pharmaceuticals' long position.

The idea behind Opus Genetics, and Telix Pharmaceuticals Limited pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.